LL-37 and Citrullinated LL-37 Modulate Immune Responses in Inflammation

Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediated immune responses, with implications for autoimmune and inflammatory diseases.

Altieri, Anthony et al.·Journal of inflammation (London·2025·Preliminary Evidencein vitro
RPEP-09911In vitroPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=not applicable
Participants
In vitro bronchial epithelial cell culture experiments

What This Study Found

Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediated immune responses, with implications for autoimmune and inflammatory diseases.

Key Numbers

Study tested LL-37 and citrullinated-LL-37 effects on multiple IL-17A/F-induced inflammatory mediators, with selective Lipocalin-2 suppression identified.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide therapeutic knowledge.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to evidence?
  • ?Next research?

Trust & Context

Key Stat:
Key finding Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediat
Evidence Grade:
Based on study design.
Study Age:
Published in 2025.
Original Title:
LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated responses and selectively suppress Lipocalin-2 in bronchial epithelial cells.
Published In:
Journal of inflammation (London, England), 22(1), 20 (2025)
Database ID:
RPEP-09911

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Study reveals how LL-37 cathelicidin and its citrullinated form differentially modulate IL-17-mediated immune responses, with implications for autoimmune and inflammatory diseases.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09911·https://rethinkpeptides.com/research/RPEP-09911

APA

Altieri, Anthony; Lloyd, Dylan; Ramotar, Padmanie; van der Does, Anne M; Hemshekhar, Mahadevappa; Mookherjee, Neeloffer. (2025). LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated responses and selectively suppress Lipocalin-2 in bronchial epithelial cells.. Journal of inflammation (London, England), 22(1), 20. https://doi.org/10.1186/s12950-025-00446-w

MLA

Altieri, Anthony, et al. "LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated responses and selectively suppress Lipocalin-2 in bronchial epithelial cells.." Journal of inflammation (London, 2025. https://doi.org/10.1186/s12950-025-00446-w

RethinkPeptides

RethinkPeptides Research Database. "LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated res..." RPEP-09911. Retrieved from https://rethinkpeptides.com/research/altieri-2025-ll37-and-citrullinatedll37-modulate

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.